Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

28.66
+0.40001.42%
Post-market: 28.800.1400+0.49%19:56 EST
Volume:4.92M
Turnover:140.67M
Market Cap:20.51B
PE:-24.42
High:29.20
Open:28.43
Low:28.10
Close:28.26
52wk High:29.20
52wk Low:8.73
Shares:715.70M
Float Shares:467.00M
Volume Ratio:0.91
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1734
EPS(LYR):-0.2371
ROE:-19.14%
ROA:-14.47%
PB:4.80
PE(LYR):-120.88

Loading ...

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (Cs)

THOMSON REUTERS
·
Feb 06

Immunovant Inc. to Announce Third Quarter Financial Results and Business Update

Reuters
·
Jan 26

Roivant Sciences Ltd. to Report Financial Results and Provide Business Update

Reuters
·
Jan 26

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

THOMSON REUTERS
·
Jan 24

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Jan 15

What Roivant Sciences (ROIV)'s Accelerated Brepocitinib Push Means For Shareholders

Simply Wall St.
·
Jan 08

Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares

Reuters
·
Jan 01

Jefferies Sets $24 Price Target for Roivant (ROIV.US), Highlights Three Key 2026 Catalysts

Stock News
·
Dec 31, 2025

Roivant Sciences CFO Richard Pulik Reports Disposal of Common Shares

Reuters
·
Dec 30, 2025

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Dec 30, 2025

Insider Confidence In December 2025's Leading Growth Companies

Simply Wall St.
·
Dec 26, 2025

Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

Director Daniel Allen Gold Reports Disposal of Roivant Sciences Ltd. Common Shares

Reuters
·
Dec 19, 2025

QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares

Reuters
·
Dec 19, 2025

Roivant Sciences CEO Matthew Gline Reports Disposal of Common Shares

Reuters
·
Dec 18, 2025

Roivant Sciences (ROIV): Reassessing Valuation After Bullish Pipeline and Patent Milestone Updates

Simply Wall St.
·
Dec 17, 2025

Vivek Ramaswamy Reports Disposal of Roivant Sciences Ltd. Common Shares

Reuters
·
Dec 16, 2025

Roivant Sciences Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Dec 16, 2025

Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 13, 2025

Roivant Sciences Ltd. : H.c. Wainwright Raises Target Price to $26 From $23

THOMSON REUTERS
·
Dec 12, 2025